Home > Forums > Long Term Plans and Actions > How can pharmaceutical companies re-evaluate their engagement strategy with HCPs?

How can pharmaceutical companies re-evaluate their engagement strategy with HCPs?

COVID19 has fundamentally disrupted delivery of healthcare, particularly in oncology. Significant work has been undertaken recently in the healthcare and life science industries to assess level of disruption and HCP perspectives on COVID19. Read the full report here.

Source: Guidehouse Life science

Topic locked

Author:

veritas
Created:
Friday, 15 May, 2020 - 09:55
Updated:
Friday, 15 May, 2020 - 09:58